Loı̈c Perchenet

3.5k total citations · 1 hit paper
44 papers, 2.3k citations indexed

About

Loı̈c Perchenet is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Molecular Biology. According to data from OpenAlex, Loı̈c Perchenet has authored 44 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 21 papers in Cardiology and Cardiovascular Medicine and 8 papers in Molecular Biology. Recurrent topics in Loı̈c Perchenet's work include Pulmonary Hypertension Research and Treatments (28 papers), Cardiac electrophysiology and arrhythmias (10 papers) and Ion channel regulation and function (8 papers). Loı̈c Perchenet is often cited by papers focused on Pulmonary Hypertension Research and Treatments (28 papers), Cardiac electrophysiology and arrhythmias (10 papers) and Ion channel regulation and function (8 papers). Loı̈c Perchenet collaborates with scholars based in Switzerland, France and United States. Loı̈c Perchenet's co-authors include Gérald Simonneau, Pavel Jansa, Adam Torbicki, Hossein Ardeschir Ghofrani, Marion Delcroix, Lewis J. Rubin, Nazzareno Galiè, Olivier Sitbon, Richard N. Channick and Sanjay Mehta and has published in prestigious journals such as New England Journal of Medicine, Journal of the American College of Cardiology and PLoS ONE.

In The Last Decade

Loı̈c Perchenet

41 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension

2013 948 citations Tomás Pulido, Richard N. Channick et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Loı̈c Perchenet Switzerland	17	1.8k	1.5k	348	295	248	44	2.3k
Koichiro Sugimura Japan	29	1.5k 0.8×	1.5k 1.0×	341 1.0×	421 1.4×	182 0.7×	104	2.5k
Linda Webster Canada	10	1.2k 0.7×	944 0.6×	187 0.5×	455 1.5×	243 1.0×	12	1.8k
Gerrit Weimann Germany	11	1.4k 0.8×	1.2k 0.8×	278 0.8×	214 0.7×	364 1.5×	44	1.8k
Roger Jeffs United States	13	951 0.5×	735 0.5×	220 0.6×	151 0.5×	88 0.4×	15	1.3k
Maria M. Jöbsis United States	6	2.7k 1.5×	2.0k 1.3×	495 1.4×	92 0.3×	255 1.0×	6	3.0k
Mikio Kakishita Japan	12	930 0.5×	1.4k 1.0×	129 0.4×	367 1.2×	52 0.2×	32	1.8k
Wolfgang Steudel United States	23	1.2k 0.7×	623 0.4×	79 0.2×	338 1.1×	574 2.3×	37	2.0k
Laurence Dewachter Belgium	19	987 0.5×	579 0.4×	91 0.3×	360 1.2×	152 0.6×	62	1.5k
Julian Strange United Kingdom	22	908 0.5×	1.2k 0.8×	152 0.4×	242 0.8×	156 0.6×	70	1.9k
Satoshi Akagi Japan	21	564 0.3×	488 0.3×	132 0.4×	184 0.6×	74 0.3×	78	1.1k

Countries citing papers authored by Loı̈c Perchenet

Since Specialization

Citations

This map shows the geographic impact of Loı̈c Perchenet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Loı̈c Perchenet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Loı̈c Perchenet more than expected).

Fields of papers citing papers by Loı̈c Perchenet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Loı̈c Perchenet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Loı̈c Perchenet. The network helps show where Loı̈c Perchenet may publish in the future.

Co-authorship network of co-authors of Loı̈c Perchenet

This figure shows the co-authorship network connecting the top 25 collaborators of Loı̈c Perchenet. A scholar is included among the top collaborators of Loı̈c Perchenet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Loı̈c Perchenet. Loı̈c Perchenet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Small, Mark, et al.. (2024). The diagnostic journey of pulmonary arterial hypertension patients: results from a multinational real-world survey. Therapeutic Advances in Respiratory Disease. 18. 2683798214–2683798214. 6 indexed citations

Quinn, Deborah A., et al.. (2023). Time to diagnosis of pulmonary hypertension and diagnostic burden: A retrospective analysis of nationwide US healthcare data. Pulmonary Circulation. 13(1). e12188–e12188. 13 indexed citations

Mouthon, Luc, Serge Poiraudeau, Margaret Vernon, et al.. (2020). Psychometric validation of the Hand Disability in Systemic Sclerosis-Digital Ulcers (HDISS-DU®) patient-reported outcome instrument. Arthritis Research & Therapy. 22(1). 3–3. 14 indexed citations

Galiè, Nazzareno, Olivier Sitbon, Martin Doelberg, et al.. (2020). Long-term outcomes in newly diagnosed pulmonary arterial hypertension (PAH) patients receiving initial triple oral combination therapy: insights from the randomised controlled TRITON study. European Heart Journal. 41(Supplement_2). 2 indexed citations

Chin, Kelly, Olivier Sitbon, Martin Doelberg, et al.. (2020). Efficacy and Safety of Initial Triple Oral Versus Initial Double Oral Combination Therapy in Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH): Results of the Randomized Controlled TRITON Study. A2928–A2928. 14 indexed citations

Scala, Lilla Di, Loı̈c Perchenet, & J. Lemarié. (2019). PRO1 MEDICAL THERAPY FOR PULMONARY ARTERIAL HYPERTENSION (PAH): AN INDIRECT TREATMENT COMPARISON OF MACITENTAN AND BOSENTAN. Value in Health Regional Issues. 19. S74–S74. 1 indexed citations

Souza, Rogério, Richard N. Channick, Marion Delcroix, et al.. (2018). Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. PLoS ONE. 13(3). e0193226–e0193226. 36 indexed citations

Mehta, Sanjay, Rogério Souza, Adam Torbicki, et al.. (2016). Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension. CHEST Journal. 151(1). 106–118. 42 indexed citations

Simonneau, Gérald, Richard N. Channick, Marion Delcroix, et al.. (2015). Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. European Respiratory Journal. 46(6). 1711–1720. 29 indexed citations

10.

Sitbon, Olivier, Richard N. Channick, Marion Delcroix, et al.. (2013). Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH). European Respiratory Journal. 42(Suppl 57). P4060–P4060. 5 indexed citations

11.

Souza, Rogério, Richard N. Channick, Marion Delcroix, et al.. (2013). Association Between WHO Functional Class and Long-term Prognosis in Patients With Pulmonary Arterial Hypertension: Data From SERAPHIN, A Randomized Controlled Study of Macitentan. CHEST Journal. 144(4). 879A–879A. 1 indexed citations

12.

Channick, Richard N., Marion Delcroix, Nazzareno Galiè, et al.. (2013). Reduction Of Pulmonary Arterial Hypertension (Pah)-Related Hospitalizations With Macitentan In The Randomized Controlled Trial Seraphin. Value in Health. 16(3). A231–A231. 3 indexed citations

13.

Channick, Richard, Marion Delcroix, Nazzareno Galiè, et al.. (2013). Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy. CHEST Journal. 144(4). 876A–876A. 2 indexed citations

14.

Pulido, Tomás, Richard N. Channick, Marion Delcroix, et al.. (2013). Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. New England Journal of Medicine. 369(9). 809–818. 948 indexed citations breakdown →

15.

Jaïs, Xavier, Andrea Maria D’Armini, Pavel Jansa, et al.. (2008). Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of the American College of Cardiology. 52(25). 2127–2134. 384 indexed citations

16.

Uriel, Nir, Guillermo Torre‐Amione, Olga Milo, et al.. (2005). Echocardiographic Ejection Fraction in Patients with Acute Heart Failure: Correlations with Hemodynamic, Clinical, and Neurohormonal Measures and Short-Term Outcome. European Journal of Heart Failure. 7(5). 815–819. 22 indexed citations

17.

Cotter, Gad, Edo Kaluski, Karl Stangl, et al.. (2004). The Hemodynamic and Neurohormonal Effects of Low Doses of Tezosentan (An Endothelin A/B Receptor Antagonist) in Patients with Acute Heart Failure. European Journal of Heart Failure. 6(5). 601–609. 51 indexed citations

18.

Mitcheson, John S., et al.. (2002). Comparison of Na+/Ca2+ exchanger current and of its response to isoproterenol between acutely isolated and short-term cultured adult ventricular myocytes. Biochemical and Biophysical Research Communications. 297(2). 302–308. 11 indexed citations

19.

Perchenet, Loı̈c, et al.. (2000). Stimulation of Na/Ca exchange by the β-adrenergic/protein kinase A pathway in guinea-pig ventricular myocytes at 37°C. Pflügers Archiv - European Journal of Physiology. 439(6). 822–828. 57 indexed citations

20.

Duval, A, Claire O. Malécot, Loı̈c Perchenet, & T. Piek. (1993). The benzodiazepine midazolam preferentially blocks inactivated Na channels in skeletal muscle fibre. Naunyn-Schmiedeberg s Archives of Pharmacology. 347(5). 541–547. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact